# Q2 2023 Financial Results & Business Update

August 8, 2023

# Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen's goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as "believes," "expects," "anticipates," "could," "would," "seeks," "aims," "plans," "potential," "will" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning Acumen's business, Acumen's ability to achieve its strategic and financial goals, including its projected use of cash, cash equivalents and marketable securities and the sufficiency of its cash resources, and the therapeutic potential of Acumen's product candidate, ACU193, including its potential for improved safety and efficacy as compared to other monoclonal antibodies in development, as well as the expectations concerning the INTERCEPT-AD trial and Acumen's planned Phase 2/3 clinical trial, including the expected timing of initiation of the trial. These statements are based upon the current beliefs and expectations of Acumen management, and are subject to certain factors, risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing safe and effective human therapeutics. Such risks may be amplified by the impacts of the COVID-19 pandemic. These and other risks concerning Acumen's programs are described in additional detail in Acumen's filings with the Securities and Exchange Commission ("SEC"), including in Acumen's most recent Annual Report Form 10-K and future filings and reports by Acumen. Copies of these and other documents are available from Acumen. Additional information will be made available in other filings that Acumen makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Acumen expressly disclaims any obligation to update or revise any forward-looking statement, except as otherwise required by law, whether, as a result of new information, future events or otherwise. In this presentation, references to cash also include cash equivalents.

# Agenda

- **Q2 2023 Business Update**

  Dan O'Connell, Chief Executive Officer

- **ACU193 Clinical Development Update**

  Dr. Eric Siemers, Chief Medical Officer

- **Q2 2023 Financial Results**

  Matt Zuga, Chief Business Officer & Chief Financial Officer

# Phase 1 Data Supports Advancing to Phase 2/3

- Rapid, dose-related, statistically significant amyloid plaque reduction observed within higher dose cohorts
- Topline results from INTERCEPT-AD trial demonstrated proof-of-mechanism for ACU193, the first clinical stage AβO-targeting antibody
- ACU193 was well-tolerated in patients with early AD; resulted in no drug-related SAEs; low rate of ARIA-E
- ACU193 approached maximal central target engagement of toxic AβOs, establishing broad therapeutic index and path to convenient monthly dosing

Exploratory measures:

- As expected, no effects observed with clinical cognitive measures in this small study of short duration
- As expected, no effects observed with MRI ASL pulse sequence in this small study of short duration
- Fluid biomarker data expected Q4 2023

**COMPELLING PROOF OF MECHANISM DEMONSTRATED**

Next Steps: Anticipated FDA Interaction 4Q 2023; Expected Phase 2 Initiation 1H 2024

# ACU193 Development Summary

- ⇒ Differentiated profile: Nonclinical and Phase 1 data consistent with toxicity of Aβ oligomers and selective binding of ACU193 to Aβ oligomers
- ⇒ Positive topline results from Phase1 study assessing safety, PK, and target engagement
- ⇒ Anticipate next clinical study, following FDA interaction in Q4 2023, starting as Phase 2 study with potential to expand to Phase 3 registration study based on interim analyses

# Acumen is Well Capitalized, With Expected Cash Runway Into 2H 2026

| MILESTONES | STATUS/ EXPECTED TIMING |
|---|---|
| Proof-of-mechanism topline results | ✓ |
| Biomarker results from Phase 1 study | Q4 2023 |
| Anticipated interaction with FDA | Q4 2023 |
| Anticipated initiation of Phase 2 trial | 1H 2024 |

**~$172M**

Cash, cash equivalents and marketable securities as of June 30, 2023

**~$122M**

In additional net proceeds from upsized public follow-on offering in July 2023

We believe that Acumen has the cash and marketable securities on hand to advance ACU193 into 2H 2026



ACUMEN